Abivax Unveils Promising Obefazimod Data at ECCO 2026

Abivax presented new findings at the 21st Annual Congress of the European Crohn’s and Colitis Organization (ECCO). The data highlighted obefazimod’s potential in treating inflammatory bowel disease, notably ulcerative colitis (UC) and Crohn’s disease (CD). The drug exhibited anti-fibrotic effects in preclinical and in vivo models, suggesting it may address unmet needs in CD.

A pooled safety analysis of the ABTECT-1 and ABTECT-2 trials showed obefazimod had comparable rates of serious adverse events and study discontinuations to placebo. Symptomatic relief began as early as week 1, with significant improvements by week 2.

Biomarker analyses indicated increased expression of miR-124 and decreased inflammatory cytokines IL-17A and IL-6, supporting obefazimod’s mechanism for restoring immune balance. Upcoming trial results, expected later in 2026, are anticipated to further define its clinical applicability.